Description of Collaborative Activity: |
The Accelerating Medicines Partnership (AMP) is a public-private partnership, between NIH, FDA, 10 biopharmaceutical companies and multiple non-profit organizations, and managed by the Foundation for NIH (FNIH), to transform the current model for developing new diagnostics and treatments by jointly identifying and validating promising biological targets for therapeutics. The ultimate goal is to increase the number of new diagnostics and therapies for patients and reduce the time and cost of developing them. AMP was launched in February 2014, with projects in three disease areas (Alzheimer’s disease; type 2 diabetes; and autoimmune disorders of rheumatoid arthritis and systemic lupus erythematous). Steering committees for each of the three disease areas, with representation from all partners, meet regularly to review ongoing progress and milestones. The steering committees are managed by FNIH under the direction of an AMP Executive Committee comprised of representatives from NIH, participating industry leaders, FDA, and non-profit organizations. |
NIH Participating Institutes/Centers/Office of the Director: |
NIA, NIAMS, NIDDK, OD/OSP |
